image
Healthcare - Biotechnology - NASDAQ - US
$ 0.8357
8.2 %
$ 77.7 M
Market Cap
-0.48
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 23, 2025.

The intrinsic value of one CRBU stock under the worst case scenario is HIDDEN Compared to the current market price of 0.836 USD, Caribou Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 23, 2025.

The intrinsic value of one CRBU stock under the base case scenario is HIDDEN Compared to the current market price of 0.836 USD, Caribou Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 23, 2025.

The intrinsic value of one CRBU stock under the best case scenario is HIDDEN Compared to the current market price of 0.836 USD, Caribou Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CRBU

image
$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0$0.5$0.5Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
9.99 M REVENUE
-71.01%
-167 M OPERATING INCOME
-43.56%
-149 M NET INCOME
-46.08%
-138 M OPERATING CASH FLOW
-48.14%
86.6 M INVESTING CASH FLOW
227.02%
16.7 M FINANCING CASH FLOW
-89.16%
2.08 M REVENUE
2.62%
-38.9 M OPERATING INCOME
-1.67%
-35.5 M NET INCOME
-2.32%
-35.5 M OPERATING CASH FLOW
-8.60%
15.9 M INVESTING CASH FLOW
-39.93%
3.86 M FINANCING CASH FLOW
1483.20%
Balance Sheet Caribou Biosciences, Inc.
image
Current Assets 219 M
Cash & Short-Term Investments 210 M
Receivables 2.09 M
Other Current Assets 7.75 M
Non-Current Assets 93.9 M
Long-Term Investments 9.28 M
PP&E 39.3 M
Other Non-Current Assets 45.4 M
66.88 %2.96 %12.54 %14.48 %Total Assets$313.3m
Current Liabilities 30.7 M
Accounts Payable 2.48 M
Short-Term Debt 1.43 M
Other Current Liabilities 26.7 M
Non-Current Liabilities 29.7 M
Long-Term Debt 25.1 M
Other Non-Current Liabilities 4.65 M
4.10 %44.31 %41.52 %7.70 %Total Liabilities$60.4m
EFFICIENCY
Earnings Waterfall Caribou Biosciences, Inc.
image
Revenue 9.99 M
Cost Of Revenue 0
Gross Profit 9.99 M
Operating Expenses 177 M
Operating Income -167 M
Other Expenses -17.5 M
Net Income -149 M
20m20m00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)(180m)(180m)10m010m(177m)(167m)18m(149m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-1667.16% OPERATING MARGIN
-1667.16%
-1491.95% NET MARGIN
-1491.95%
-58.95% ROE
-58.95%
-47.59% ROA
-47.59%
-58.65% ROIC
-58.65%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Caribou Biosciences, Inc.
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)(160m)(160m)202020202021202120222022202320232024202420252025
Net Income -149 M
Depreciation & Amortization 3.93 M
Capital Expenditures -4.88 M
Stock-Based Compensation 16.7 M
Change in Working Capital -5.11 M
Others -9.97 M
Free Cash Flow -143 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Caribou Biosciences, Inc.
image
Wall Street analysts predict an average 1-year price target for CRBU of $3 , with forecasts ranging from a low of $3 to a high of $3 .
CRBU Lowest Price Target Wall Street Target
3 USD 258.98%
CRBU Average Price Target Wall Street Target
3 USD 258.98%
CRBU Highest Price Target Wall Street Target
3 USD 258.98%
Price
Max Price Target
Min Price Target
Average Price Target
4444333322221111Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 9
6. Ownership
Insider Ownership Caribou Biosciences, Inc.
image
Sold
0-3 MONTHS
14.4 K USD 3
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
20.4 K USD 1
0-3 MONTHS
24.7 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Shareholders to Connect NEW YORK, NY / ACCESS Newswire / April 10, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Shareholders to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / April 6, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 3 weeks ago
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / April 3, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 4 weeks ago
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / April 1, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Investors to Connect NEW YORK, NY / ACCESS Newswire / March 30, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 1 month ago
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / March 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Reach Out NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Caribou Biosciences, Inc. (CRBU) And Encourages Stockholders to Connect NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 1 month ago
Caribou Biosciences, Inc. (CRBU) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / March 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Caribou Biosciences, Inc. (CRBU) and Encourages Stockholders to Learn More About the Investigation NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 1 month ago
Bronstein, Gewirtz & Grossman, LLC Encourages Caribou Biosciences, Inc. (CRBU) Investors to Inquire about Securities Investigation NEW YORK, NY / ACCESS Newswire / March 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Caribou Biosciences, Inc. ("Caribou" or "the Company") (NASDAQ:CRBU). Investors who purchased Caribou securities prior to July 14, 2023, and continue to hold to the present, are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/CRBU. accessnewswire.com - 1 month ago
Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Lags Revenue Estimates Caribou Biosciences, Inc. (CRBU) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.39 per share a year ago. zacks.com - 1 month ago
8. Profile Summary

Caribou Biosciences, Inc. CRBU

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 77.7 M
Dividend Yield 0.00%
Description Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. It has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California.
Contact 2929 7th Street, Berkeley, CA, 94710 https://cariboubio.com
IPO Date July 23, 2021
Employees 147
Officers Dr. Steven B. Kanner Ph.D. Chief Scientific Officer Ms. Amy Figueroa C.F.A. Vice President of Investor Relations & Corporate Communications Mr. Timothy P. Kelly M.B.A. Chief Technology Officer Mr. Daniel Poon Vice President of Operations & Information Technology Ms. Reigin Zawadzki Chief People Officer Mr. Ryan Fischesser Interim Principal Accounting Officer & Controller Mr. Sriram Ryali M.B.A. Chief Financial Officer Ms. Barbara G. McClung Esq., J.D. Chief Legal Officer & Corporate Secretary Ms. Ruhi A. Khan M.B.A. Chief Business Officer Dr. Rachel E. Haurwitz Ph.D. Co-Founder, Chief Executive Officer, President & Director